3/5
09:21 am
medp
Medpace Holdings (MEDP) Is Up 6.3% After Q4 Revenue Beats Peers And Analyst Forecasts Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Medpace Holdings (MEDP) Is Up 6.3% After Q4 Revenue Beats Peers And Analyst Forecasts Has The Bull Case Changed? [Yahoo! Finance]
3/4
05:51 am
medp
Medpace (MEDP) was upgraded by Royal Bank Of Canada to "moderate buy".
Low
Report
Medpace (MEDP) was upgraded by Royal Bank Of Canada to "moderate buy".
3/3
08:43 am
medp
Medpace (MEDP) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $522.00 price target on the stock.
Medium
Report
Medpace (MEDP) is now covered by Royal Bank Of Canada. They set an "outperform" rating and a $522.00 price target on the stock.
2/25
06:41 pm
medp
Evaluating Medpace Holdings (MEDP) After A Sharp 27% One-Month Pullback [Yahoo! Finance]
Low
Report
Evaluating Medpace Holdings (MEDP) After A Sharp 27% One-Month Pullback [Yahoo! Finance]
2/23
12:33 pm
medp
Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health Stocks Trade Down, What You Need To Know [Yahoo! Finance]
Low
Report
Medpace, Revvity, Azenta, Bio-Techne, and Oscar Health Stocks Trade Down, What You Need To Know [Yahoo! Finance]
2/19
05:25 pm
medp
MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm
Low
Report
MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm
2/18
09:00 am
medp
Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility
Medium
Report
Medpace Holdings Under Investigation After Book-to-Bill Miss Exposes Cancellation Surge and Pipeline Fragility
2/18
07:01 am
medp
Medpace (NASDAQ:MEDP) was upgraded by analysts at TD Cowen from a "sell" rating to a "hold" rating.
Low
Report
Medpace (NASDAQ:MEDP) was upgraded by analysts at TD Cowen from a "sell" rating to a "hold" rating.
2/16
03:36 pm
medp
Another celebrity chef to open restaurant in Cincy. It's sushi this time [USA TODAY]
Low
Report
Another celebrity chef to open restaurant in Cincy. It's sushi this time [USA TODAY]
2/13
07:01 am
medp
Medpace (NASDAQ:MEDP) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating.
Low
Report
Medpace (NASDAQ:MEDP) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating.
2/13
01:38 am
medp
Medpace Holdings (MEDP) Is Down 23.1% After Mixed 2025 Results and 2026 Outlook - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Medpace Holdings (MEDP) Is Down 23.1% After Mixed 2025 Results and 2026 Outlook - Has The Bull Case Changed? [Yahoo! Finance]
2/12
04:38 pm
medp
Assessing Medpace (MEDP) Valuation After A Sharp Share Price Pullback And Backlog Concerns [Yahoo! Finance]
Low
Report
Assessing Medpace (MEDP) Valuation After A Sharp Share Price Pullback And Backlog Concerns [Yahoo! Finance]
2/11
10:08 pm
medp
Medpace (MEDP) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Medpace (MEDP) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
2/11
10:59 am
medp
Medpace (NASDAQ:MEDP) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
Low
Report
Medpace (NASDAQ:MEDP) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets.
2/11
10:13 am
medp
Medpace (NASDAQ:MEDP) was given a new $582.00 price target on by analysts at Mizuho.
Low
Report
Medpace (NASDAQ:MEDP) was given a new $582.00 price target on by analysts at Mizuho.
2/11
09:51 am
medp
Medpace (NASDAQ:MEDP) had its price target lowered by analysts at Barclays PLC from $525.00 to $500.00. They now have an "underweight" rating on the stock.
Low
Report
Medpace (NASDAQ:MEDP) had its price target lowered by analysts at Barclays PLC from $525.00 to $500.00. They now have an "underweight" rating on the stock.
2/11
09:06 am
medp
Medpace (NASDAQ:MEDP) was given a new $460.00 price target on by analysts at BMO Capital Markets.
Medium
Report
Medpace (NASDAQ:MEDP) was given a new $460.00 price target on by analysts at BMO Capital Markets.
2/11
08:03 am
medp
Medpace (NASDAQ:MEDP) had its price target lowered by analysts at Leerink Partners from $575.00 to $485.00. They now have a "market perform" rating on the stock.
Medium
Report
Medpace (NASDAQ:MEDP) had its price target lowered by analysts at Leerink Partners from $575.00 to $485.00. They now have a "market perform" rating on the stock.
2/11
08:03 am
medp
Medpace (NASDAQ:MEDP) had its price target lowered by analysts at Truist Financial Corporation from $555.00 to $539.00. They now have a "hold" rating on the stock.
Medium
Report
Medpace (NASDAQ:MEDP) had its price target lowered by analysts at Truist Financial Corporation from $555.00 to $539.00. They now have a "hold" rating on the stock.
2/11
02:11 am
medp
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial [Yahoo! Finance]
Medium
Report
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial [Yahoo! Finance]
2/10
04:06 pm
medp
Medpace Q4 Earnings Call Highlights [Yahoo! Finance]
Medium
Report
Medpace Q4 Earnings Call Highlights [Yahoo! Finance]
2/10
04:06 pm
medp
Medpace Holdings Inc (MEDP) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
Medium
Report
Medpace Holdings Inc (MEDP) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... [Yahoo! Finance]
2/10
02:00 pm
medp
Medpace (NASDAQ:MEDP) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $564.00 price target on the stock.
Low
Report
Medpace (NASDAQ:MEDP) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. They now have a $564.00 price target on the stock.
2/10
12:11 pm
medp
Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Medpace Holdings, Inc. (MEDP) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/10
12:10 pm
medp
Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts [Seeking Alpha]
Low
Report
Medpace outlines 2026 revenue growth of up to 12.8% amid backlog normalization and metabolic trial shifts [Seeking Alpha]